Clinical Trial Update: Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate a combination of BI1744CL and tiotropium bromide in patients with chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI1744CL
• tiotropium bromide (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2015-08-13